The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study
Osteoporosis International · 2026
DOI: 10.1007/s00198-026-07950-6 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Osteoporosis International, 2026. Verfasst von Annika Vestergaard Kvist und 3 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark. annika.k@rn.dk. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Osteoporotic Fractures, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Aalborg University Hospital.
Abstract (Originalsprache)
To examine whether GLP1-RA is associated with increased fracture risk, we compared 337,648 people with fractures to 675,296 people without fractures. Our adjusted analysis found that people with fractures tended to use GLP1-RA less often than people without fractures. This suggests that GLP1-RA may reduce fracture risk. BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists were introduced as a treatment for type 2 diabetes mellitus with weight loss as a beneficial side effect. Since then, the medications have been approved as weight-loss medication. However, rapid and substantial weight loss can lead to bone loss and increased fracture risk. METHODS: We identified persons aged 30-90 years with a fracture between 2017 and 2021 and matched them 1:2 with fracture-free controls by sex and year of birth. Conditional logistic regression models were used to estimate odds ratios (ORs) for any fracture and major osteoporotic fracture (MOF) associated with GLP-1 receptor agonist use. Analyses were adjusted for relevant risk factors. RESULTS: A total of 337,648 fracture cases and 675,296 fracture-free controls were included. In the unadjusted analyses, GLP-1 receptor agonist use did not differ between cases and controls (any fracture OR [confidence intervals (CI)], 1.00 [0.97-1.04]; MOF OR [CI], 0.96 [0.90-1.02]). In the adjusted analyses, GLP-1 receptor agonists were used less frequently in the group that sustained any fracture (OR [CI], 0.94 [0.90-0.97]) or MOF (OR [CI], 0.88 [0.83-0.94]) compared to the controls. CONCLUSION: GLP-1 receptor agonists may reduce fracture risk, suggesting a potential protective effect on bone health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark. annika.k@rn.dk.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. annika.k@rn.dk.
- Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.
Förderung
- Aalborg University Hospital
Zitieren
APA
Kvist, A. V., Andersen, S. S., Vestergaard, P., & Viggers, R. (2026). The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study. Osteoporosis International. https://doi.org/10.1007/s00198-026-07950-6
Vancouver
Kvist AV, Andersen SS, Vestergaard P, Viggers R. The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study. Osteoporosis International. 2026. doi:10.1007/s00198-026-07950-6
BibTeX
@article{Kvist2026,
author = {Kvist, Annika Vestergaard and Andersen, Sally Søgaard and Vestergaard, Peter and Viggers, Rikke},
title = {The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study},
journal = {Osteoporosis International},
year = {2026},
doi = {10.1007/s00198-026-07950-6}
}
EUVIMED